Harbour BioMed: The CRHX-101 project has been spun off to Adrenyx, which is expected to list on Nasdaq in the first half of 2027.

date
18/11/2026
Harbour BioMed announces that its partner Spruce Biosciences has spun off its CRHX-101 project into Adrenyx Biosciences, a newly established wholly-owned subsidiary of Spruce. Adrenyx is expected to list on Nasdaq in the first half of 2027. Following the completion of the planned pro rata distribution of Adrenyx common shares to Spruce shareholders, Harbour BioMed expects to hold equity interests in both Spruce and Adrenyx simultaneously. CRHX-101 is a monoclonal antibody designed and developed for the treatment of congenital adrenal hyperplasia. Adrenyx intends to submit an Investigational New Drug application for CRHX-101 to the U.S. Food and Drug Administration and subsequently initiate clinical development.